Ben Yong

Chief Med & Dev Officer

Ben Yong has filed 6 SEC Form 4 filings (6 transaction rows) across 2 companies, including BBOT, CRBP, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Oct 5, 2026.

On the most recent filing, Ben Yong is listed as Director at Corbus Pharmaceuticals Holdings, Inc. Inside the rolling window, Ben Yong reported no open-market purchases and 1 open-market sale totaling $16K in CRBP.

Companies traded

Other insiders at BBOT

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$16K

reported sales (SEC code S)

Companies

2

in the rolling window

Source
CRBPSale$16KSep 15SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Ben Yong made?

Ben Yong has filed 6 SEC Form 4 filings (6 transaction rows) across 2 companies, including BBOT, CRBP since 2026.

Which companies does Ben Yong trade?

Ben Yong has filed SEC Form 4 disclosures for 2 companies, including BBOT, CRBP.

When was Ben Yong's most recent SEC Form 4 filing?

Ben Yong's most recent SEC Form 4 filing on Tracefour is dated Oct 5, 2026.

What is Ben Yong's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Ben Yong is listed as Chief Med & Dev Officer.

What is Ben Yong's total buy and sell value in the current window?

Inside the rolling retention window, Ben Yong bought $0 and sold $16K based on SEC Form 4 filings.

What was Ben Yong's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 2,000 CRBP shares on 2026-09-14, worth $16K, per SEC Form 4 filings.